Arcadia Biosciences Logo
US0390142042
A2JSFW
RKDA

Arcadia Biosciences

Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 5,47 € (+3117,65 %). La mediana es de 5,47 € (+3117,65 %).

Comprar
  4
Mantener
  1
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Arcadia Biosciences secures $4 million through private placement

    Arcadia Biosciences raised approximately $4 million in gross proceeds through a private placement, selling 3,883,496 common shares or prepaid warrants at $1.03 per share. The offering also included Series A-1 and A-2 investment options with an exercise price of $0.91; A-1 will be exercisable after shareholder approval, A-2 is immediately exercisable. H.C. Wainwright & Co. acted as sole placement agent; net proceeds are intended for working capital and general corporate purposes. The transaction is notable given a current market capitalization of $2.08 million; the company reports a current ratio of 3.79 and plans to file registration statements for resale. » Más en de.investing.com


  • Arcadia Biosciences secures $4 million through private placement

    Arcadia Biosciences sold 3,883,496 common shares or prepaid warrants at a price of $1.03 each, generating gross proceeds of approximately $4 million. The transaction includes A‑1 and A‑2 warrants with an exercise price of $0.91; A‑1 warrants are valid for five years following shareholder approval, A‑2 warrants are immediately exercisable and expire 24 months after the registration statement becomes effective. H.C. Wainwright & Co. is acting as exclusive placement agent; the proceeds are intended for working capital and general corporate purposes, and the closing is expected subject to customary conditions. » Más en de.investing.com


  • Arcadia Biosciences dismisses Deloitte and appoints Ramirez Jimenez International as new auditor

    Arcadia Biosciences dismissed Deloitte & Touche as its independent auditor effective March 30 and appointed Ramirez Jimenez International CPAs (RJI) to audit the quarter ended March 31, 2026 and the fiscal year ended December 31, 2026. Deloitte’s reports for 2024 and 2025 contained no adverse opinions but included an explanatory paragraph regarding going concern; the company disclosed material weaknesses in internal control over financial reporting for 2025, notably a lack of segregation of duties and deficient IT controls due to reduced staffing. Deloitte was authorized to provide RJI with information on the matters; Arcadia reports no disagreements with Deloitte. » Más en de.investing.com


  • Arcadia Biosciences stock rises after termination of Roosevelt deal

    Arcadia Biosciences stock rose about 9% in pre-market trading after Roosevelt Resources terminated the securities exchange agreement dated December 4, 2024, as of December 24, 2025, in accordance with the contract. CEO T.J. Schaefer said the company will resume the review process for strategic alternatives and pointed to operational streamlining, cost reductions and growth of the coconut water brand Zola. The company still holds roughly 2.7 million common shares of Above Food Ingredients and expects additional consideration related to the sale of GoodWheat, which, together with the NASDAQ listing, should favor strategic transactions. » Más en de.investing.com


  • Arcadia Biosciences schedules annual general meeting for December 19, 2025

    Arcadia Biosciences sets its 2025 annual general meeting for December 19 and says it will publish the time, location and agenda in the definitive proxy statement filed with the SEC. Shareholders must submit proposals or director nominations in writing by close of business on November 3, 2025. The company is keeping the annual meeting separate from a possible special meeting related to a Securities Exchange Agreement with Roosevelt Resources. In addition, CFO Mark Kawakami resigned effective September 12; Thomas J. Schaefer was appointed interim CFO and will take on the role in addition to his duties as CEO with no change to his compensation. Analysts see significant upside, with a $12 price target versus the current price of $4.14. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, Arcadia Biosciences tuvo unos ingresos de 1,43 M € y un beneficio neto de 1,55 M €
(EUR) septiembre de 2026
YoY
Ingresos 1,43 M 28,83 %
Beneficio bruto 758,37 mil 112,91 %
Beneficio neto 1,55 M 112,41 %
EBITDA 1,55 M 111,92 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
281,57 mil €
Número de acciones
1,55 M
Máximo/mínimo de 52 semanas
3,53 € - 0,10 €
Dividendos No
Beta
0,59
Ratio P/E
-0,02
Ratio PEG
0,00
Ratio P/B
0,50
Ratio P/S
0,06

Perfil de la empresa

Arcadia Biosciences, Inc. produce y comercializa productos de salud y bienestar de origen vegetal en Estados Unidos. La empresa se dedica al desarrollo de mejoras de cultivos, principalmente en trigo, para mejorar la economía agrícola mediante el aumento del rendimiento de los cultivos en el campo, así como de su valor como ingredientes alimentarios, de sus productos de salud y bienestar y de su viabilidad para aplicaciones industriales. La compañía fue constituida en 2002 y tiene su sede en Davis, California.

Nombre
Arcadia Biosciences
CEO
Thomas J. Schaefer
Sede Davis, tx
Estados Unidos
Sitio web
Sector
Consumo básico
Industria
Productos alimenticios
Salida a bolsa
15/05/2015
Empleados 8

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
RKDA
Frankfurt
17DN.F
München
17DN.MU
🍪

Parqet  usa cookies. Más información